The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1145
December 9, 2002
View Complete Issue         Table of Contents 2019 
Gamma Hydroxybutyrate (Xyrem) for Narcolepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gamma Hydroxybutyrate (Xyrem) for Narcolepsy
December 9, 2002 (Issue: 1145)
The FDA has approved use of gamma hydroxybutyrate (sodium oxybate is the official generic name; Xyrem - Orphan Medical) for oral treatment of cataplexy in patients with narcolepsy. Gamma hydroxybutyrate (GHB), a metabolite of gamma-aminobutyric acid...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Gamma Hydroxybutyrate (Xyrem) for Narcolepsy
Article code: 1145a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.